Epibiotech Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	449.62	387.85
Other Revenue	0	-
Revenue	449.62	387.85
Revenue Growth (YoY)	15.93%	-
Cost of Revenue	177.38	163.21
Gross Profit	272.25	224.64
Selling, General & Admin	1,527	1,292
Research & Development	2,976	1,755
Other Operating Expenses	63.67	45.69
Operating Expenses	5,311	3,466
Operating Income	-5,038	-3,242
Interest Expense	-91.47	-73.66
Interest & Investment Income	64.42	51.29
Currency Exchange Gain (Loss)	53.22	67.72
Other Non Operating Income (Expenses)	-7.36	1.03
EBT Excluding Unusual Items	-5,020	-3,195
Gain (Loss) on Sale of Assets	-38.21	-
Pretax Income	-5,058	-3,195
Net Income	-5,058	-3,195
Net Income to Common	-5,058	-3,195
Shares Outstanding (Basic)	2	2
Shares Outstanding (Diluted)	2	2
Shares Change (YoY)	0.60%	-
EPS (Basic)	-2966.00	-1885.00
EPS (Diluted)	-2966.00	-1885.00
Free Cash Flow	-5,124	-4,569
Free Cash Flow Per Share	-3004.95	-2695.24
Gross Margin	60.55%	57.92%
Operating Margin	-1120.59%	-835.82%
Profit Margin	-1124.91%	-823.86%
Free Cash Flow Margin	-1139.68%	-1177.98%
EBITDA	-4,294	-2,868
D&A For EBITDA	743.99	373.93
EBIT	-5,038	-3,242
Advertising Expenses	42.45	30.53

Source: S&P Global Market Intelligence. Standard template. Financial Sources.